Childhood systemic sclerosis

Current Opinion in Rheumatology

Volumn 19, Issue 6, 2007, Pages 592-597

  Zulian, Francesco ^a,b   Martini, Giorgia ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Department of Pediatrics   (Italy)

Author keywords

Autoantibodies; Classification; Organ involvement; Systemic sclerosis

Indexed keywords

ANTIBIOTIC AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROKINETIC AGENT; PROSTACYCLIN; PROSTANOID; PROTON PUMP INHIBITOR; RITUXIMAB; SILDENAFIL; SITAXSENTAN;

CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; IMMUNOREACTIVITY; MEDICAL RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; SYSTEMIC SCLEROSIS;

CHILD; HUMANS; MULTICENTER STUDIES AS TOPIC; SCLERODERMA, SYSTEMIC;

EID: 34948895946     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282f01625     Document Type: Review

References (26)

1. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-590.
2. Zulian F, Woo P, Athreya BH, Laxer RM, et al. The PRES/ACR/EULAR provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum 2007; 57:203-212. Study describing an international project aimed to define a provisional set of classification criteria for SSc in children on the basis of clinical data of real patients following a consensus-based methodology.
3. Scalapino K, Arkachaisri T, Lucas M, et al. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol 2006; 33:1004-1013. Interesting report on the clinical features of childhood-onset SSc followed at one center and comparison with adult-onset cases.
4. Martini G, Foeldvari I, Russo R, et al. Systemic sclerosis in childhood: clinical and immunological features of 153 patients in an international database. Arthritis Rheum 2006; 54:3971-3978. A comprehensive study describing the clinical and immunological features of a cohort of 153 children with SSc from a multicenter multinational database.
5. Murata M, Sato S, Komura K, et al. Clinical characteristics of juvenile systemic sclerosis in Japanese. J Rheumatol 2005; 32:1850-1852.
6. Della Rossa A, Valentini G, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. I: Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 2001; 60:585-591.
7. Merkel PA, Clements PJ, Reveille JD, et al. Current status of outcome measures development for clinical trials in systemic sclerosis: report from OMERACT 6. J Rheumatol 2003; 30:1630-1647.
8. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655-2666.
9. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54:3962-3970.
10. Furst D, Khanna D, Matucci-Cerinic M, et al. Systemic sclerosis: continuing progress in developing clinical measures of response. J Rheumatol 2007; 34:1194-1200.
11. Foeldvari I, Wierk A. Healthy children have a significantly increased skin score assessed with the modified Rodnan skin score. Rheumatology (Oxford) 2006; 45:76-78. First pediatric study evaluating the MRSS in normal children.
12. Singh G, Athreya BH, Fries JF, et al. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994; 37:1761-1769.
13. Len C, Goldenberg J, Bosi Ferraz M, et al. Cross-cultural reliability of Childhood Health Assessment Questionnaire. J Rheumatol 1994; 21:2349-2352.
14. Feldman BM, Ayling-Campos A, Luy L, et al. Measuring disability in juvenile dermatomyositis: validity of the childhood health assessment questionnaire. J Rheumatol 1995; 22:326-331.
15. Landgraf JM, Abetz L, Ware JE. The CHQ user's manual. Boston: The Health Institute, New England Medical Center; 1996.
16. Raat H, Bonsel GJ, Essink-Bot ML, et al. Reliability and validity of comprehensive health status measures in children: the Child Health Questionnaire in relation to the Health Utilities Index. J Clin Epidemiol 2002; 55:67-76.
17. Zulian F, Corona F, Gerloni V, et al. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases. Rheumatology (Oxford) 2004; 43:229-233.
18. Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR/EUSTAR recommendations for the treatment of systemic sclerosis (SSc) [abstract]. Ann Rheum Dis 2007; 66 (SII):213.
19. Zulian F, Kowal-Bielecka O, Miniati I, et al. Preliminary agreement of the Pediatric Rheumatology European Society (PRES) on the EUSTAR/EULAR recommendations for the management of systemic sclerosis in children [abstract]. Proceedings of the 14th Pediatric Rheumatology Congress, Istanbul, Turkey; 5-9 September 2007.
20. Liossis SNC, Bounas A, Andonopulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 2006; 45:1005-1008. Pilot study showing the efficacy of MMF associated with small doses of corticosteroids in patients with diffuse SSc and recent alveolitis.
21. Nihtyanova SI, Brough GM, Black CM, Denton CP. Mychophenolate mofetil in diffuse cutaneous systemic sclerosis: a retrospective analysis. Rheumatology 2007; 46:442-445.
22. Adams AB, Barillas-Arias L, Angeles ST, et al. Cyclophosphamide and rituximab combination therapy for the treatment of juvenile-onset scleroderma: 6 patient case series [abstract]. Arthritis Rheum 2006; 54 (Suppl):S169.
23. Martini G, Zulian F. Clinical features and outcome in juvenile systemic sclerosis (JSSc): data from the international Padua database of 153 patients [abstract]. Clin Exp Rheumatol 2006; 24 (1 Suppl 40):S57.
24. Quartier P, Bonnet D, Fournet JC, et al. Severe cardiac involvement in children with systemic sclerosis and myositis. J Rheumatol 2002; 29:1767-1773.
25. Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002; 81:154-167.
26. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical and serologic features and survival in 1012 Italian patients. Medicine 2002; 81:139-153.